{"id":"ezn-2279","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Liver enzyme elevation"},{"rate":null,"effect":"Platelet count reduction"}]},"_chembl":{"chemblId":"CHEMBL578875","moleculeType":"Small molecule","molecularWeight":"502.52"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"EZN-2279 targets and degrades apoC-III mRNA, leading to reduced apoC-III protein levels. ApoC-III is an inhibitor of lipoprotein lipase and is associated with elevated triglycerides and cardiovascular risk. By reducing apoC-III, the drug aims to lower triglyceride levels and improve lipid profiles in patients with hypertriglyceridemia.","oneSentence":"EZN-2279 is an antisense oligonucleotide that inhibits apolipoprotein C-III (apoC-III) expression to reduce triglycerides and improve lipid metabolism.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:12:09.371Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertriglyceridemia"},{"name":"Familial chylomicronemia syndrome"}]},"trialDetails":[{"nctId":"NCT01420627","phase":"PHASE3","title":"EZN-2279 in Patients With ADA-SCID","status":"COMPLETED","sponsor":"Leadiant Biosciences, Inc.","startDate":"2014-01-24","conditions":"ADA-SCID, Adenosine Deaminase Deficiency, Severe Combined Immunodeficiency","enrollment":7}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["rADA"],"phase":"phase_3","status":"active","brandName":"EZN-2279","genericName":"EZN-2279","companyName":"Leadiant Biosciences, Inc.","companyId":"leadiant-biosciences-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"EZN-2279 is an antisense oligonucleotide that inhibits apolipoprotein C-III (apoC-III) expression to reduce triglycerides and improve lipid metabolism. Used for Hypertriglyceridemia, Familial chylomicronemia syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}